NEW YORK, April 30, 2014 /PRNewswire/ -- The Law
Offices of Vincent Wong are
investigating potential claims against the Board of Directors of
Furiex Pharmaceuticals, Inc. (NasdaqGS: FURX) ("Furiex") in
connection with the sale of the Company to Forest Laboratories,
Inc. ("Forest").
Click here to learn about the case:
http://docs.wongesq.com/FURX-Info-Request-Form-214. There is
no cost or obligation to you.
Under the terms of the transaction, Furiex shareholders will
receive $95.00 per share in cash for
each share of Furiex stock they own. The transaction has a total
approximate value of $1.1 billion. An
additional $30.00 per share
($360 million in aggregate) may be
payable to shareholders in a Contingent Value Right (CVR) based on
the status of eluxodoline, Furiex's lead product, as a controlled
drug following approval. The investigation concerns whether the
Furiex Board of directors breached their fiduciary duties to
stockholders by failing to adequately shop the Company before
agreeing to enter into this transaction, and whether Forest is
underpaying for Furiex shares.
If you own common stock in Furiex and wish to obtain additional
information, please contact Vincent Wong,
Esq. either via email vw@wongesq.com, by telephone at
212.425.1140, or visit
http://docs.wongesq.com/FURX-Info-Request-Form-214.
Vincent Wong, Esq. is an
experienced attorney that has represented investors in securities
litigations involving financial fraud and violations of shareholder
rights. Attorney advertising. Prior results do not guarantee
similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com
SOURCE The Law Offices of Vincent
Wong